Table 2.
List of genetic polymorphisms related to susceptibility of DILI development.
| Genetic Variation | Association | Drug Studied | DILI Association | References |
|---|---|---|---|---|
| Drug transporters genes | ||||
| ABCB1 3435T | Transporter | Nevirapine | ↓ Risk | [169,170] |
| ABCB11 1331C | Transporter | Various | ↑ Risk | [171,172] |
| ABCB4 haplotypes | Transporter | Various | ↑ Risk | [171] |
| ABCC2 haplotypes | Transporter | Various | ↑ Risk | [164,173] |
| Cytochrome P450 genes | ||||
| CYP2B6*6 | Phase I | Efavirenz | ↑ Risk | [174] |
| Nevirapine | ↑ Risk | [175] | ||
| Anti TBC | ↓ Risk | [176] | ||
| CYP2B6 rs7254579 | Phase I | Ticlopidine | ↑ Risk | [177] |
| CYP2C8 haplotypes | Phase I | Diclofenac | ↑ Risk | [164] |
| Repaglinide | ↑ Risk | [164] | ||
| CYP2E1 c1/c1 | Phase I | Isoniazid | ↑ Risk | [178] |
| Phase II enzymes genes | ||||
| GST T1/M1 null | Phase II | Various | ↑ Risk | [179,180,181,182,183] |
| GPX1 198T | Phase II | Various | ↑ Risk | [184] |
| NAT2 slow acetylators | Phase II | Anti-TBC | ↑ Risk | [177,180,181] |
| SOD2 47C | Phase II | Various | ↑ Risk | [182,184] |
| UGT2B7*2 | Phase II | Diclofenac | ↑ Risk | [164] |
| UGT1A6/1A9 | Phase II | Tolcapone | ↑ Risk | [185,186] |
| Others | ||||
| PTPN2 | Tyrosine phosphatase | Various | ↑ Risk | [187] |
| POLG | mtDNA polymerase γ | Valproic acid | ↑ Risk | [100] |